

Quantikine[®] ELISA

Human Amyloid β (aa1-40) Immunoassay

Catalog Number DAB140

For the quantitative determination of human Amyloid beta (amino acids 1-40) concentrations in cell culture supernates and cerebrospinal fluid.

This package insert must be read in its entirety before using this product.
For research use only. Not for use in diagnostic procedures.

TABLE OF CONTENTS

SECTION	PAGE
INTRODUCTION	1
PRINCIPLE OF THE ASSAY.....	2
LIMITATIONS OF THE PROCEDURE	3
TECHNICAL HINTS.....	3
MATERIALS PROVIDED & STORAGE CONDITIONS	4
OTHER SUPPLIES REQUIRED	5
PRECAUTIONS.....	5
SAMPLE COLLECTION & STORAGE.....	5
REAGENT PREPARATION.....	6
ASSAY PROCEDURE	7
CALCULATION OF RESULTS.....	8
TYPICAL DATA.....	8
PRECISION	9
RECOVERY.....	9
LINEARITY.....	9
SENSITIVITY	10
CALIBRATION	10
SAMPLE VALUES.....	10
SPECIFICITY.....	10
REFERENCES	11
PLATE LAYOUT	12

MANUFACTURED AND DISTRIBUTED BY:

USA & Canada | R&D Systems, Inc.

614 McKinley Place NE, Minneapolis, MN 55413, USA
TEL: (800) 343-7475 (612) 379-2956 FAX: (612) 656-4400
E-MAIL: info@RnDSystems.com

DISTRIBUTED BY:

UK & Europe | R&D Systems Europe, Ltd.

19 Barton Lane, Abingdon Science Park, Abingdon OX14 3NB, UK
TEL: +44 (0)1235 529449 FAX: +44 (0)1235 533420
E-MAIL: info@RnDSystems.co.uk

China | R&D Systems China Co., Ltd.

24A1 Hua Min Empire Plaza, 726 West Yan An Road, Shanghai PRC 200050
TEL: +86 (21) 52380373 FAX: +86 (21) 52371001
E-MAIL: info@RnDSystemsChina.com.cn

INTRODUCTION

Amyloid beta peptides (Amyloid β or A β) are proteolytic fragments of the Amyloid Precursor Protein (APP), and their formation into fibrils plays an integral role in Alzheimer's disease pathology. Amyloid β fibrils constitute the major protein component of senile plaques that accumulate in the brain of Alzheimer's patients. Amyloid plaque accumulation is increased in the presence of hypoxia, traumatic brain injury, and chronic inflammation (1, 2). Amyloid β also directly exerts multiple effects on neurons (1, 3). APP is a multifunctional transmembrane protein that consists of a 682 amino acid (aa) extracellular domain (ECD), a 24 aa transmembrane segment, and a 47 aa cytoplasmic domain. Its ECD contains two heparin binding domains, one copper binding domain, a BPTI/Kunitz inhibitor domain, and a collagen binding domain. Alternative splicing generates multiple isoforms including the most prevalent APP695, APP751, and APP770 which contain various deletions or substitutions in the ECD. The Amyloid β peptide sequences extend from the extracellular juxtamembrane region into the transmembrane segment.

APP is subject to proteolytic cleavage at multiple sites that may or may not result in the generation of Amyloid β . In the non-amyloidogenic pathway, the APP ECD is shed by β -secretase cleavage (ADAM10) within the Amyloid β sequence, thereby preventing the formation of Amyloid β peptides (4). In the amyloidogenic pathway, APP is cleaved by BACE (β -secretase activity) just N-terminal to the Amyloid β sequence (5, 6). This releases a slightly shorter ECD fragment known as APP β . Following amyloidogenic ECD shedding, intramembrane cleavage of the remaining portion by β -secretase/Presenilin protein complexes generates the Amyloid β peptides 1-40 or 1-42 (7-9). These peptides are 40 and 42 aa in length, respectively, and share Asp672 as their N-terminal residue. β -secretase cleavage also releases the intracellular domain (AICD) which translocates to the nucleus and regulates the transcription of a wide variety of genes (10). Soluble fragments of the APP ECD are released into cerebrospinal fluid (CSF), interstitial fluid in brain, plasma, and urine (11-14). They can be further cleaved to generate a 35 kDa fragment which binds the receptor DR6 and triggers axonal pruning and neurodegeneration (15).

Amyloid β peptides can associate intracellularly into dimers, higher order oligomers, and insoluble fibrils (16-18). They enhance the hyperphosphorylation of Tau and the formation of neurofibrillary tangles, another hallmark of Alzheimer's disease (19). Amyloid β also forms fibrils with ApoE and binds to the prion protein PrP(C) (20, 21). Of the various forms of Amyloid β , oligomers are the most potent at impairing cognitive function, inhibiting long term potentiation (LTP) in hippocampal neurons, and inducing neuronal oxidative stress (16, 22, 23). In contrast, monomeric Amyloid β can be protective against excitotoxic neuronal cell death (24). Amyloid β can directly disrupt the integrity of neuronal membranes (25). The neurotoxicity of Amyloid β is increased by its *in vivo* glycation or pyroglutamylation (26, 27). Amyloid β interaction with RAGE induces neuronal mitochondrial dysfunction, oxidative stress, inflammatory activation of astrocytes and microglia, and transport of circulating Amyloid β across the blood brain barrier into the brain (28-30). It also induces neuroinflammation through interactions with TLR2 (31). Extracellular Amyloid β can be degraded by Neprilysin or Insulysin/IDE, and Amyloid β clearance is impaired in Alzheimer's (32-35).

INTRODUCTION *CONTINUED*

Amyloid β peptides exert direct actions on several neurotransmitter receptors, and APP metabolism is regulated by the activity of these receptors. Amyloid β binds and activates the nicotinic acetylcholine alpha 7 receptor, leading to neuroprotection, enhanced synaptic plasticity and memory formation, and the upregulation of acetylcholinesterase (36-38). Amyloid β activation of NMDA and AMPA receptors, however, leads to mitochondrial dysfunction and neuronal apoptosis (39). Amyloid β inhibits the release of dopamine and GABA in response to muscarinic receptor activation (40). The non-amyloidogenic processing of APP is induced by multiple triggers including Substance P or the activation of particular subtypes of muscarinic, nicotinic, purinergic, serotonin, NMDA, or metabotropic glutamate receptors (41-47).

The Quantikine Human Amyloid β (aa1-40) Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human Amyloid β (aa1-40) in cell culture supernates and cerebrospinal fluid. It contains synthetic human Amyloid β (aa1-40) and antibodies raised against the synthetic peptide. Results obtained for naturally occurring human Amyloid β (aa1-40) showed linear curves that were parallel to the standard curves obtained using the kit standards. These results indicate that this kit can be used to determine relative mass values for natural human Amyloid β (aa1-40).

PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for human Amyloid β (aa1-40) has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any Amyloid β (aa1-40) present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked monoclonal antibody specific for human Amyloid β (aa1-40) is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Amyloid β (aa1-40) bound in the initial step. The color development is stopped and the intensity of the color is measured.

LIMITATIONS OF THE PROCEDURE

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
- The kit should not be used beyond the expiration date on the kit label.
- Do not mix or substitute reagents with those from other lots or sources.
- If samples generate values higher than the highest standard, dilute the samples with Diluent RD2-7 and repeat the assay.
- Any variation in standard diluent, operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.
- Variations in sample collection, processing, and storage may cause sample value differences.
- This assay is designed to eliminate interference by other factors present in biological samples. Until all factors have been tested in the Quantikine Immunoassay, the possibility of interference cannot be excluded.

TECHNICAL HINTS

- When mixing or reconstituting protein solutions, always avoid foaming.
- To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer, and/or rotating the plate 180 degrees between wash steps may improve assay precision.
- Substrate Solution should remain colorless until added to the plate. Keep Substrate Solution protected from light. Substrate Solution should change from colorless to gradations of blue.
- Stop Solution should be added to the plate in the same order as the Substrate Solution. The color developed in the wells will turn from blue to yellow upon addition of the Stop Solution. Wells that are green in color indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution.

MATERIALS PROVIDED & STORAGE CONDITIONS

Store the unopened kit at 2-8 °C. Do not use past kit expiration date.

PART	PART #	DESCRIPTION	STORAGE OF OPENED/ RECONSTITUTED MATERIAL
Human Amyloid β (aa1-40) Microplate	894651	96 well polystyrene microplate (12 strips of 8 wells) coated with a monoclonal antibody specific for human Amyloid β (aa1-40).	Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of the zip-seal. May be stored for up to 1 month at 2-8 °C.*
Human Amyloid β (aa1-40) Standard	894653	Synthetic human Amyloid β (aa1-40) peptide in a buffered protein base with preservatives; lyophilized. <i>Refer to the vial label for reconstitution volume.</i>	Aliquot and store for up to 1 month at ≤ -20 °C in a manual defrost freezer.* Avoid repeated freeze-thaw cycles.
Human Amyloid β (aa1-40) Conjugate	894652	21 mL of monoclonal antibody specific for human Amyloid β (aa1-40) conjugated to horseradish peroxidase with preservatives.	May be stored for up to 1 month at 2-8 °C.*
Diluent RD2-7	896015	21 mL of a buffered protein base with preservatives.	
Wash Buffer Concentrate	895003	21 mL of a 25-fold concentrated solution of buffered surfactant with preservative. <i>May turn yellow over time.</i>	
Color Reagent A	895000	12 mL of stabilized hydrogen peroxide.	
Color Reagent B	895001	12 mL of stabilized chromogen (tetramethylbenzidine).	
Stop Solution	895032	6 mL of 2 N sulfuric acid.	
Plate Sealers	N/A	4 adhesive strips.	

* Provided this is within the expiration date of the kit.

OTHER SUPPLIES REQUIRED

- Microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
- Pipettes and pipette tips.
- Deionized or distilled water.
- Squirt bottle, manifold dispenser, or automated microplate washer.
- 500 mL graduated cylinder.
- Test tubes for dilution of standards and samples.
- Human Amyloid β Controls (optional; available from R&D Systems).

PRECAUTIONS

The Stop Solution provided with this kit is an acid solution.

Some components in this kit contain ProClin[®] which may cause an allergic skin reaction. Avoid breathing mist.

Color Reagent B may cause skin, eye, and respiratory irritation. Avoid breathing fumes.

Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling. Please refer to the MSDS on our website prior to use.

SAMPLE COLLECTION & STORAGE

The sample collection and storage conditions listed below are intended as general guidelines. Sample stability has not been evaluated.

Cell Culture Supernates - Remove particulates by centrifugation and assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Cerebrospinal Fluid - Freeze sample within one hour of collection to avoid aggregation. Store samples at ≤ -70 °C. Thaw samples on ice to prevent aggregation. Avoid repeated freeze-thaw cycles.

Note: Amyloid β is labile in cerebrospinal fluid and can become undetectable over time.

All trademarks and registered trademarks are the property of their respective owners.

REAGENT PREPARATION


The Human Amyloid β (aa1-40) Conjugate must remain at 2-8 °C during use. Bring all other reagents to room temperature before use.

Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 20 mL of Wash Buffer Concentrate to deionized or distilled water to prepare 500 mL of Wash Buffer.

Substrate Solution - Color Reagents A and B should be mixed together in equal volumes within 15 minutes of use. Protect from light. 200 μ L of the resultant mixture is required per well.

Human Amyloid β (aa1-40) Standard - Refer to the vial label for reconstitution volume. Reconstitute the Human Amyloid β (aa1-40) Standard with deionized or distilled water. This reconstitution produces a stock solution of 100 ng/mL. Mix the standard to ensure complete reconstitution and allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions.

Pipette 200 μ L of Diluent RD2-7 into each tube. Use the stock solution to produce a dilution series (below). Mix each tube thoroughly before the next transfer. The 50 ng/mL standard serves as the high standard. Diluent RD2-7 serves as the zero standard (0 ng/mL).



ASSAY PROCEDURE

The Amyloid β (aa1-40) Conjugate must remain at 2-8 °C during use. Bring all other reagents and samples to room temperature before use. It is recommended that all samples and standards be assayed in duplicate.

1. Prepare all reagents, working standards, and samples as directed in the previous sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
3. Add 100 μ L of Diluent RD2-7 to each well.
4. Add 25 μ L of Standard, control, or sample per well. Cover with the adhesive strip provided. **Incubate for 2 hours at 2-8 °C.** A plate layout is provided to record the standards and samples assayed.
5. Aspirate each well and wash, repeating the process two times for a total of three washes. Wash by filling each well with Wash Buffer (400 μ L) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
6. Add 200 μ L of **cold** Human Amyloid β (aa1-40) Conjugate to each well. Cover with a new adhesive strip. **Incubate for 2 hours at 2-8 °C.**
7. Repeat the aspiration/wash as in step 5.
8. Add 200 μ L of Substrate Solution to each well. Incubate for 30 minutes at room temperature on the benchtop. **Protect from light.**
9. Add 50 μ L of Stop Solution to each well. The color in the wells should change from blue to yellow. If the color in the wells is green or the color change does not appear uniform, gently tap the plate to ensure thorough mixing.
10. Determine the optical density of each well within 30 minutes, using a microplate reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.

CALCULATION OF RESULTS


Average the duplicate readings for each standard, control, and sample and subtract the average zero standard optical density (O.D.).

Create a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the human Amyloid β (aa1-40) concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data.

If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

TYPICAL DATA

This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.



(ng/mL)	O.D.	Average	Corrected
0	0.012 0.012	0.012	—
0.781	0.034 0.034	0.034	0.022
1.56	0.058 0.059	0.059	0.047
3.13	0.113 0.126	0.120	0.108
6.25	0.266 0.267	0.267	0.255
12.5	0.564 0.593	0.579	0.567
25	1.193 1.248	1.221	1.209
50	2.075 2.151	2.113	2.101

PRECISION

Intra-assay Precision (Precision within an assay)

Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays)

Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.

Sample	Intra-Assay Precision			Inter-Assay Precision		
	1	2	3	1	2	3
n	20	20	20	20	20	20
Mean (ng/mL)	5.14	15.9	31.8	4.99	14.9	29.6
Standard deviation	0.177	0.917	2.16	0.298	1.21	2.72
CV (%)	3.4	5.8	6.8	6.0	8.1	9.2

RECOVERY

The recovery of human Amyloid β (aa1-40) spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type	Average % Recovery	Range
Cell culture media (n=4)	94	80-108%
Cerebrospinal fluid (n=4)	91	83-99%

LINEARITY

To assess linearity of the assay, samples containing and/or spiked with high concentrations of human Amyloid β (aa1-40) were diluted with Diluent RD2-7 to produce samples with values within the dynamic range of the assay.

		Cell culture media (n=4)	Cerebrospinal fluid (n=4)
1:2	Average % of Expected	104	101
	Range (%)	100-108	85-110
1:4	Average % of Expected	102	100
	Range (%)	98-108	83-114
1:8	Average % of Expected	99	103
	Range (%)	95-106	89-112
1:16	Average % of Expected	100	107
	Range (%)	92-104	97-115

SENSITIVITY

Twenty-one assays were evaluated and the minimum detectable dose (MDD) of human Amyloid β (aa1-40) ranged from 0.031-0.147 ng/mL. The mean MDD was 0.069 ng/mL.

The MDD was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.

CALIBRATION

This immunoassay is calibrated against synthetic human Amyloid β (aa1-40).

SAMPLE VALUES

Cerebrospinal Fluid - Purchased samples were evaluated for the presence of human Amyloid β (aa1-40) in this assay. No medical histories were available for the donors used in this study.

Sample Type	Mean of Detectable (ng/mL)	% Detectable	Range (ng/mL)
Cerebrospinal fluid (n=45)	6.90	98	ND-17.2

ND=Non-detectable

SPECIFICITY

This assay recognizes natural human Amyloid β (aa1-40).

The factors listed below were prepared at 500 ng/mL in Calibrator Diluent and assayed for cross-reactivity. Preparations of the following factors at 500 ng/mL in a mid-range recombinant human Amyloid β control were assayed for interference. No significant cross-reactivity or interference was observed.

Recombinant human:

ApoER2
Apolipoprotein E2
Apolipoprotein E3
Apolipoprotein E4
LDL R
LRP-1 Cluster II
LRP-1 Cluster III
LRP-1 Cluster IV

Synthetic proteins:

human Amyloid β (aa1-42)
human Amyloid β (aa17-40)
human Amyloid β (aa22-40)
mouse/rat Amyloid β (aa1-40)
mouse/rat Amyloid β (aa1-42)

Synthetic human Amyloid β (aa2-40) cross-reacts approximately 55%.

Synthetic human Amyloid β (aa3-40) cross-reacts approximately 4.4%.

Synthetic human Amyloid β (aa4-40), (aa11-40), and [Pyr3] Amyloid β (aa3-40) interfere at concentrations > 100 ng/mL.

Synthetic human [Pyr11] Amyloid β (aa11-40) interferes at concentrations > 10 ng/mL.

REFERENCES

1. Chami, L. and F. Checler (2012) *Mol. Neurodegen.* **7**:52.
2. Saido, T.C. (2013) *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* **89**:321.
3. Govoni, S. *et al.* (2013) *Curr. Pharmaceut. Des.* July 11 Epub. PMID 23859550
4. Skovronsky, D.M. *et al.* (2000) *J. Biol. Chem.* **275**:2568.
5. Vassar, R. *et al.* (1999) *Science* **286**:735.
6. Yan, R. *et al.* (1999) *Nature* **402**:533.
7. Kimberly, W.T. *et al.* (2000) *J. Biol. Chem.* **275**:3173.
8. Li, Y.M. *et al.* (2000) *Nature* **405**:689.
9. Herreman, A. *et al.* (2000) *Nat. Cell Biol.* **2**:461.
10. Pardossi-Piquard, R. and F. Checler (2012) *J. Neurochem.* **120** Suppl 1:109.
11. Seubert, P. *et al.* (1992) *Nature* **359**:325.
12. Brody, D.L. *et al.* (2008) *Science* **321**:1221.
13. Ghiso, J. *et al.* (1997) *FEBS Lett.* **408**:105.
14. Toledo, J.B. *et al.* (2013) *Alzheimer's Res. Ther.* **5**:8.
15. Nikolaev, A. *et al.* (2009) *Nature* **457**:981.
16. Walsh, D.M. *et al.* (2002) *Nature* **416**:535.
17. Hong, L. *et al.* (2010) *J. Phys. Chem. B.* **114**:11261.
18. Kuo, Y.M. *et al.* (1996) *J. Biol. Chem.* **271**:4077.
19. Gotz, J. *et al.* (2001) *Science* **293**:1491.
20. Rushworth, J.V. *et al.* (2013) *J. Biol. Chem.* **288**:8935.
21. Naslund, J. *et al.* (1995) *Neuron* **15**:219.
22. Cleary, J.P. *et al.* (2004) *Nat. Neurosci.* **8**:79.
23. Huang, S.M. *et al.* (2006) *J. Biol. Chem.* **281**:17941.
24. Giuffrida, M.L. *et al.* (2009) *J. Neurosci.* **29**:10582.
25. Sepulveda, F.J. *et al.* (2010) *PLoS ONE* **5**:e11820.
26. Li, X.H. *et al.* (2013) *Cell Death Dis.* **4**:e673.
27. Nussbaum, J.M. *et al.* (2012) *Nature* **485**:651.
28. Takuma, K. *et al.* (2009) *Proc. Natl. Acad. Sci. USA* **106**:20021.
29. Yan, S.D. *et al.* (1996) *Nature* **382**:685.
30. Deane, R. *et al.* (2003) *Nat. Med.* **9**:907.
31. Liu, S. *et al.* (2012) *J. Immunol.* **188**:1098.
32. Shirotani, K. *et al.* (2001) *J. Biol. Chem.* **276**:21895.
33. Iwata, N. *et al.* (2001) *Science* **292**:1550.
34. Farris, W. *et al.* (2003) *Proc. Natl. Acad. Sci. USA* **100**:4162.
35. Mawuenyeta, K.G. *et al.* (2010) *Science* **330**:1774.
36. Puzzo, D. *et al.* (2008) *J. Neurosci.* **28**:14537.
37. Lilja, A.M. *et al.* (2011) *J. Alzheimers Dis.* **23**:335.
38. Fodero, L.R. *et al.* (2004) *J. Neurochem.* **88**:1186.
39. Alberdi, E. *et al.* (2010) *Cell Calcium* **47**:264.
40. Grilli, M. *et al.* (2010) *Neuroscience* **167**:482.
41. Marolda, R. *et al.* (2012) *Neuropharmacology* **62**:1954.
42. Lee, R.K. *et al.* (1995) *Proc. Natl. Acad. Sci. USA* **92**:8083.
43. Cirrito, J.R. *et al.* (2011) *Proc. Natl. Acad. Sci. USA* **108**:14968.
44. Camden, J.M. *et al.* (2005) *J. Biol. Chem.* **280**:18696.
45. Hoey, S.E. *et al.* (2009) *J. Neurosci.* **29**:4442.
46. Delarasse, C. *et al.* (2011) *J. Biol. Chem.* **286**:2596.
47. Nitsch, R.M. *et al.* (1992) *Science* **258**:304.

PLATE LAYOUT

Use this plate layout to record standards and samples assayed.

12									
11									
10									
9									
8									
7									
6									
5									
4									
3									
2									
1									
	A	B	C	D	E	F	G	H	

NOTES

NOTES